Short Term Trading Week Starting: 26 Mar, page-176

STTCOMP ACW, FA Long
Actinogen Medical is an ASX-listed biotechnology company developing innovative treatments for Alzheimer’s disease and the cognitive decline associated with neurodegenerative diseases and metabolic diseases, like Type 2 diabetes.
Market Cap: $38m / Cash: $5.5m

Detailed Description/Catalyst
Top 20 shareholders own 49% of the company.
No1 shareholder owns 6.81% and concept of this drug was first discovered by them, by accident, giving then the best possible position to make a call on this drug. As such they have come on board and taken the biggest stake at No1.
At Phase 2 testing and human trials have already been inadvertently tested.

Taken from the most recent presentation:


I attended their recent road show in Melbourne and I was sold by the story.
Best bet is to read their most recent presentation as it details the story fairly well.

***DISCLAIMER: Don’t take as financial advice as I am not qualified/licenced to give it.***